We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
Read MoreHide Full Article
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in McKesson (MCK - Free Report) ten years ago? It may not have been easy to hold on to MCK for all that time, but if you did, how much would your investment be worth today?
McKesson's Business In-Depth
With that in mind, let's take a look at McKesson's main business drivers.
McKesson Corporation, headquartered in Irving, TX, is one of the largest global healthcare companies and the leading pharmaceutical distributor in North America. The company operates across four business segments: U.S. Pharmaceutical, which distributes branded, generic, and specialty drugs; RxTS, which provides patient access, affordability, and third-party logistics services for biopharma manufacturers and payors; Medical-Surgical Solutions, supplying alternate-site providers such as physician offices and home health; and International, primarily focused in Canada. Specialty pharmaceuticals, oncology services, and GLP-1 medications for diabetes and obesity are key growth engines. In FY25, GLP-1 revenues alone reached nearly $41 billion.
McKesson is streamlining its portfolio. It has completed the sale of Canadian operations, is exiting Norway, and plans to spin off its Medical-Surgical unit. Simultaneously, it is expanding its U.S. Oncology Network through acquisitions of PRISM Vision and Core Ventures, adding hundreds of new providers. These moves aim to increase exposure to higher-margin specialty and oncology services while reducing reliance on lower-margin wholesale distribution.
Notably, McKesson’s role in the COVID-19 response was reflected in the collaboration with the U.S. government's COVID-19 vaccine distribution effort, wherein McKesson was selected as the centralized distributor of refrigerated and frozen COVID-19 vaccines and the ancillary kits used to administer those vaccines.
FY26 at a Glance
Revenues in fiscal 2026 were $403.4 billion, up 12% from fiscal 2025, and adjusted EPS was $39.11, up 18% year over year. Segment revenues were led by North American Pharmaceutical at $336.7 billion, followed by Oncology & Multispecialty at $48.4 billion, Medical-Surgical Solutions at $11.5 billion, and Prescription Technology Solutions at $5.8 billion. Segment operating profit margins were 1.09% for North American Pharmaceutical, 2.37% for Oncology & Multispecialty, 17.98% for Prescription Technology Solutions, and 8.15% for Medical-Surgical Solutions.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For McKesson, if you bought shares a decade ago, you're likely feeling really good about your investment today.
According to our calculations, a $1000 investment made in September 2016 would be worth $4,795.36, or a gain of 379.54%, as of September 1, 2026, and this return excludes dividends but includes price increases.
Compare this to the S&P 500's rally of 254.05% and gold's return of 225.98% over the same time frame.
Analysts are forecasting more upside for MCK too.
McKesson combines scale in North American pharmaceutical distribution with faster-growing oncology, multispecialty and biopharma services. Specialty volumes, provider expansion and access solutions continue to broaden the earnings mix, while disciplined capital deployment supports per-share growth. Fiscal 2027 guidance was raised after first-quarter operating profit increased across the core growth platforms. These strengths are balanced by customer concentration, evolving drug-pricing and reimbursement rules, and variability in logistics and Medical-Surgical profitability. The planned separation of Medical-Surgical also adds financing and execution complexity. With durable operating momentum offset by policy, concentration and portfolio-transition risks, the risk-reward profile remains balanced for investors.
Over the past four weeks, shares have rallied 7.03%, and there have been 5 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries.
The fear of missing out, or FOMO, also plays a factor in investing, especially with particular tech giants, as well as popular consumer-facing stocks.
What if you'd invested in McKesson (MCK - Free Report) ten years ago? It may not have been easy to hold on to MCK for all that time, but if you did, how much would your investment be worth today?
McKesson's Business In-Depth
With that in mind, let's take a look at McKesson's main business drivers.
McKesson Corporation, headquartered in Irving, TX, is one of the largest global healthcare companies and the leading pharmaceutical distributor in North America. The company operates across four business segments: U.S. Pharmaceutical, which distributes branded, generic, and specialty drugs; RxTS, which provides patient access, affordability, and third-party logistics services for biopharma manufacturers and payors; Medical-Surgical Solutions, supplying alternate-site providers such as physician offices and home health; and International, primarily focused in Canada. Specialty pharmaceuticals, oncology services, and GLP-1 medications for diabetes and obesity are key growth engines. In FY25, GLP-1 revenues alone reached nearly $41 billion.
McKesson is streamlining its portfolio. It has completed the sale of Canadian operations, is exiting Norway, and plans to spin off its Medical-Surgical unit. Simultaneously, it is expanding its U.S. Oncology Network through acquisitions of PRISM Vision and Core Ventures, adding hundreds of new providers. These moves aim to increase exposure to higher-margin specialty and oncology services while reducing reliance on lower-margin wholesale distribution.
Notably, McKesson’s role in the COVID-19 response was reflected in the collaboration with the U.S. government's COVID-19 vaccine distribution effort, wherein McKesson was selected as the centralized distributor of refrigerated and frozen COVID-19 vaccines and the ancillary kits used to administer those vaccines.
FY26 at a Glance
Revenues in fiscal 2026 were $403.4 billion, up 12% from fiscal 2025, and adjusted EPS was $39.11, up 18% year over year. Segment revenues were led by North American Pharmaceutical at $336.7 billion, followed by Oncology & Multispecialty at $48.4 billion, Medical-Surgical Solutions at $11.5 billion, and Prescription Technology Solutions at $5.8 billion. Segment operating profit margins were 1.09% for North American Pharmaceutical, 2.37% for Oncology & Multispecialty, 17.98% for Prescription Technology Solutions, and 8.15% for Medical-Surgical Solutions.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For McKesson, if you bought shares a decade ago, you're likely feeling really good about your investment today.
According to our calculations, a $1000 investment made in September 2016 would be worth $4,795.36, or a gain of 379.54%, as of September 1, 2026, and this return excludes dividends but includes price increases.
Compare this to the S&P 500's rally of 254.05% and gold's return of 225.98% over the same time frame.
Analysts are forecasting more upside for MCK too.
McKesson combines scale in North American pharmaceutical distribution with faster-growing oncology, multispecialty and biopharma services. Specialty volumes, provider expansion and access solutions continue to broaden the earnings mix, while disciplined capital deployment supports per-share growth. Fiscal 2027 guidance was raised after first-quarter operating profit increased across the core growth platforms. These strengths are balanced by customer concentration, evolving drug-pricing and reimbursement rules, and variability in logistics and Medical-Surgical profitability. The planned separation of Medical-Surgical also adds financing and execution complexity. With durable operating momentum offset by policy, concentration and portfolio-transition risks, the risk-reward profile remains balanced for investors.
Over the past four weeks, shares have rallied 7.03%, and there have been 5 higher earnings estimate revisions in the past two months for fiscal 2026 compared to none lower. The consensus estimate has moved up as well.